title: Surgical resection of urological tumor metastases following medical treatment.
abstract: BACKGROUND
  The rate of systemic metastases is about 20% in testicular germ cell tumors, 25% to 30% in prostate cancer, 30% in urothelial carcinoma with muscle invasion, and 50% in renal-cell carcinoma. This article is a critical review of current data on the resection of metastases of urological tumors after systemic drug treatment.
  
  
  METHODS
  Review of pertinent publications retrieved by a selective literature search.
  
  
  RESULTS
  No pertinent prospective, randomized trials, meta-analyses, or Cochrane reviews have been published. The publications available for review include guidelines and retrospective studies with evidence levels ranging from IIB to III. For non-seminomatous germ cell tumors with tumor markers that are negative or have reached a plateau after chemotherapy, resection of retroperitoneal, intra-abdominal, and intrathoracic metastases with curative intent is now the treatment of choice at clinical reference centers. For urothelial carcinoma that has gone into partial remission after systemic chemotherapy, with full resectability, the resection of metastases prolongs survival from about 13 months to 31-41 months. For prostatic carcinoma with solitary, intrapelvic lymph-node metastases and PSA less than 4 ng/mL, the resection of metastases prolongs 5-year progression-free survival in 40% to 50% of cases. There is, however, no indication for the resection of retro-peritoneal, visceral, or bony metastases. In renal-cell carcinoma, the resection of pulmonary or hepatic metastases is associated with a 5-year survival rate of 40% to 50% or 62%, respectively, and should thus be made a component of the treatment plan for this disease. The indication for resecting metastases of urological cancers should always be established by an interdisciplinary tumor board in the light of the existing scientific evidence.
  
  
  CONCLUSIONS
  The resection of metastases of some types of urological cancer after chemotherapy can prolong progression-free and overall survival. This form of treatment deserves consideration as a component of individual care and of the interdisciplinary treatment plan for urological cancers.
authors.affiliation: Department of Urology, University Hospital Aachen.
authors.forename: Axel
authors.initials: A
authors.lastname: Heidenreich
authors.forename: Stefan
authors.initials: S
authors.lastname: Wilop
authors.forename: Michael
authors.initials: M
authors.lastname: Pinkawa
authors.forename: Daniel
authors.initials: D
authors.lastname: Porres
authors.forename: David
authors.initials: D
authors.lastname: Pfister
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D059146:Metastasectomy; D020360:Neoadjuvant Therapy; D017410:Practice Guidelines as Topic; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D013899:Thoracic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*